Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-01-20FDA Approved: PAROXETINE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' original application for Paroxetine, a generic selective serotonin reuptake inhibitor. The approval expa…
-
FDA approval · 2017-01-06FDA Approved: DULOXETINE — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approved an Original Application (ANDA 208706) for duloxetine from Quallent Pharmaceuticals Health LLC, establishing a generic version o…
-
FDA approval · 2017-01-04FDA Approved: CYMBALTA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Cymbalta (duloxetine hydrochloride) from Eli Lilly and Company.
-
FDA label_change · 2017-01-04FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental labeling change for Effexor XR (venlafaxine hydrochloride) submitted by Viatris Specialty LLC. The supplemental …
-
FDA approval · 2017-01-04FDA Approved: LEXAPRO — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Lexapro (escitalopram) filed by Allergan, Inc. This is a supplemental approval of the NDA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
The FDA approved a supplemental application for venlafaxine hydrochloride from Vertical Pharmaceuticals, LLC, likely related to labeling cha…
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Venlafaxine from Sun Pharmaceutical Industries, Inc., indicating approval of a change to the exi…
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental ANDA for venlafaxine by Heritage Pharmaceuticals (Avet) to bring a generic version to the market.
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for venlafaxine hydrochloride (generic venlafaxine) from Aurobindo Pharma Limited.
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for Venlafaxine from Alembic Pharmaceuticals Inc. under an approved ANDA.
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application from BluePoint Laboratories for Venlafaxine (venlafaxine hydrochloride), a generic antidepressan…
-
FDA approval · 2017-01-04FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride (venlafaxine HCl) from Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS trial_result · 2016-12-29Clinical Trial Update: Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly [Phase 4]
Phase 4 clinical trial evaluating pharmacological treatment of generalized anxiety disorder in elderly adults has completed, with results po…
-
FDA approval · 2016-12-22FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis Division of Pfizer Inc.
-
FDA approval · 2016-12-16FDA Approved: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for the generic chlordiazepoxide and amitriptyline hydrochloride combination from Mylan Pharmaceutic…
-
FDA approval · 2016-12-16FDA Approved: ALPRAZOLAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for alprazolam from Mylan Pharmaceuticals Inc., authorizing changes to the product under the NDA.
-
FDA approval · 2016-12-16FDA Approved: ALPRAZOLAM — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental Abbreviated New Drug Application for alprazolam, a generic benzodiazepine manufactured by Par Health USA, LLC.
-
FDA approval · 2016-12-16FDA Approved: ALPRAZOLAM — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s supplemental application for alprazolam, resulting in a generic alprazolam product.
-
FDA approval · 2016-12-16FDA Approved: XANAX XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Xanax XR (alprazolam) submitted by Viatris Specialty LLC. The action updates the labeling under …
-
CLINICAL_TRIALS trial_result · 2016-12-07Clinical Trial Update: Attention Training for Generalized Anxiety Disorder [NA]
This update notes the completion of a clinical trial studying attention training as an intervention for Generalized Anxiety Disorder.
-
CLINICAL_TRIALS trial_result · 2016-11-30Clinical Trial Update: Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR [Phase 4]
A Phase 4 trial comparing the effectiveness of long-term versus short-term treatment with venlafaxine XR for generalized anxiety disorder ha…
-
FDA approval · 2016-11-25FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for a venlafaxine hydrochloride generic product from BluePoint Laboratories under ANDA077653. Th…
-
CLINICAL_TRIALS trial_result · 2016-11-15Clinical Trial Update: POC Study in Partially Responsive Generalized Anxiety Disorder [Phase 2]
Pfizer conducted a Phase 2 proof-of-concept study in partially responsive Generalized Anxiety Disorder. The study was terminated and results…
-
FDA approval · 2016-11-08FDA Approved: HYDROXYZINE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for hydroxyzine hydrochloride by Chartwell RX, LLC.
-
CLINICAL_TRIALS trial_result · 2016-11-01Clinical Trial Update: Internet-based Treatment of Generalized Anxiety Disorder [NA]
A completed clinical trial evaluating an internet-based treatment for Generalized Anxiety Disorder.